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The first confirmed Rift Valley fever outbreak outside Africa was reported in September 2000, in the Ara-
bian Peninsula. As of February 2001, a total of 884 hospitalized patients were identified in Saudi Arabia,
with 124 deaths. In Yemen, 1,087 cases were estimated to have occurred, with 121 deaths. Laboratory
diagnosis of Rift Valley fever virus (RVFV) infections included virus genetic detection and characterization
of clinical specimens by reverse transcription-polymerase chain reaction, in addition to serologic tests and
virus isolation. Genetic analysis of selected regions of virus S, M, and L RNA genome segments indicated
little genetic variation among the viruses associated with disease. The Saudi Arabia and Yemen viruses
were almost identical to those associated with earlier RVF epidemics in East Africa. Analysis of S, M, and
L RNA genome segment sequence differences showed similar phylogenetic relationships among these
viruses, indicating that genetic reassortment did not play an important role in the emergence of this virus in
the Arabian Peninsula. These results are consistent with the recent introduction of RVFV into the Arabian
Peninsula from East Africa.
ift Valley fever (RVF) (caused by Rift Valley fever virus
[RVFV], family Bunyaviridae) is an emerging epidemic
disease of humans and livestock, as well as an important
endemic problem in sub-Saharan Africa. The virus is transmit-
ted to livestock and humans by the bite of infected mosquitoes
or exposure to tissues or blood of infected animals. Massive
epizootics are typically observed in livestock during times of
unusually high and sustained rainfall because of the presence
of breeding sites and overabundance of adult competent mos-
quito vectors (1). Infections caused by RVFV are characterized
by severe disease and abortion in livestock, particularly sheep
and cattle. Persons in the epidemic region are at high risk for
RVFV infection, potentially leading to thousands of human
cases. Humans infected with RVFV typically have self-limited
febrile illness, but retinal degeneration (5–10%), hemorrhagic
fever (<1%), or encephalitis (<1%) may also develop (2).
We report the first confirmed outbreak of RVF outside
Africa, in the Kingdoms of Saudi Arabia and Yemen. On Sep-
tember 10, 2000, the Ministry of Health in Saudi Arabia began
to receive reports of unexplained hemorrhagic fever in humans
near the Saudi-Yemeni border, with associated animal deaths
and abortions. Patient samples from the outbreak were sent to
the Centers for Disease Control and Prevention (CDC), where
laboratory analysis confirmed the cases as being caused by
RVFV. Genetic analysis was performed on all three viral RNA
segments from human clinical samples, and the sequences were
compared with previously characterized RVFV isolates to
determine their genetic relatedness and geographic distribution.
Materials and Methods
Clinical Specimens
On September 15, 2000, acute-phase sera from four seri-
ously ill, hospitalized patients with unexplained hemorrhagic
fever were received by Special Pathogens Branch, CDC for
diagnostic assessment (Table 1). The shipment also contained
sera from nine close contacts, mainly household members. A
second shipment, which arrived on September 20, 2000, con-
tained acute-phase sera from an additional 15 hospitalized
patients and 12 contacts. Subsequent specimens from Saudi
Arabia and Yemen were submitted for confirmation and more
detailed analysis. All work with potentially infectious material
was performed in a biosafety level 4 maximum containment
facility.
Virus Antigen, IgM, and IgG Detection in Patient Sera
Patient sera were tested for the presence of RVFV or
Crimean-Congo hemorrhagic fever virus (C-CHFV) antigen,
or immunoglobulin (Ig) M or IgG antibodies reactive with
these viruses and Alkhurma virus, a member of the tick-borne
encephalitis (TBE) complex that was recently discovered in
Saudi Arabia (4). RVFV and C-CHFV antigen-capture assays
were performed in an enzyme-linked immunosorbent assay
(ELISA) format essentially as described (5). The RVFV assay
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Table 1. Results of diagnostic testing of initial Saudi Arabian Rift Valley fever outbreak specimensa
Patient IDb Categoryc
ALK C-CHFV RVFV
IgM IgG Ag IgM IgG Ag IgM IgG ISOL PCR
10901 Suspected case-patient - - - - - POS - - POS POS
10902 Suspected case-patient - - - - - POS - - POS POS
10904 Suspected case-patient - - - - - - POS POS POS POS
10905 Suspected case-patient - - - - - POS - - POS POS
10906 Contact - - - - - - - - - -
10907 Contact - - - - - - - - - -
10908 Contact - - - - - - - - - -
10909 Contact - - - - - - - - - -
10910 Contact - - - - - - - - - -
10911 Contact - - - - - - - - POS POS
10912 Contact - - - - - - POS - - -
10913 Contact - - - - - - - - - -
10914 Contact - - - - - - - - - -
10931 Suspected case-patient - - - - - POS - - POS POS
10933 Suspected case-patient - - - - - - POS POS - -
10935 Suspected case-patient - - - - - - - - - -
10937 Suspected case-patient - - - - - POS POS - POS POS
10939 Suspected case-patient - - - - - - POS - - -
10941 Suspected case-patient - - - - - - - - - -
10943 Suspected case-patient - - - - - POS - - POS POS
10945 Suspected case-patient - - - - - - POS - POS POS
10947 Suspected case-patient - - - - - POS POS - POS POS
10949 Suspected case-patient - - - - - - POS - POS POS
10951 Suspected case-patient - - - - - POS - - POS POS
10953 Suspected case-patient - - - - - POS - - POS POS
10955 Suspected case-patient - - - - - POS POS - POS -
10957 Suspected case-patient - - - - - POS - - POS POS
10959 Suspected case-patient - - - - - POS - - POS POS
10960 Contact - - - - - - - - - -
10961 Contact - - - - - - - - - -
10962 Contact - - - - - - POS - - -
10963 Contact - - - - - - POS - - -
10964 Contact - - - - - - POS POS - -
10965 Contact - - - - - - - - - -
10966 Contact - - - - - - - - - -
10967 Contact - - - - - - - - - -
10968 Contact - - - - - - - - - -
10969 Contact - - - - - - - - - -
10970 Contact - - - - - - POS - - -
10971 Contact - - - - - - - - - -
aRVFV, Rift Valley fever virus; ALK, Alkhurma virus; Ig, immunoglobulin; C-CHFV, Crimean-Congo hemorrhagic fever virus; ISOL, virus isolation; PCR, polymerase chain reac-
tion; POS, positive results; -, negative results.
bInitial specimens were all from persons living in Jizan Province.
cSuspected case-patients were defined as described earlier (3).Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1417
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used polyclonal hyperimmune ascitic fluid raised against
RVFV strain Zagazig 501 as the capture antibody and rabbit
hyperimmune serum raised against RVFV Zagazig 501 as the
detector antibody. The C-CHFV assay used a sheep hyperim-
mune serum raised against a South African C-CHFV strain as
the detector antibody, and a mouse hyperimmune ascitic fluid
raised against C-CHFV strain IbAr10200 as the capture anti-
bodies (6). IgM antibody titers were determined by IgM anti-
body–capture ELISA, with RVFV, C-CHFV, or Alkhurma
virus–infected cell slurry prepared as described (5). IgG anti-
body titers were determined by using RVFV, C-CHFV, and
Alkhurma virus–infected cell antigens in an ELISA format
similar as to that described previously (5).
Virus Isolation and RNA Extraction
Viral RNA was obtained directly from patient blood or
serum collected during the outbreak or from virus isolated
from patient serum that was passaged once in Vero E6 cells. A
virus stock was prepared by placing 100 µL of patient serum
(200010901) onto a confluent monolayer of Vero E6 cells in a
T-25 flask. After the virus was allowed to absorb for 1 h at
37°C, 6–7 mL of Dulbecco, modified Eagle medium supple-
mented with 5% fetal calf serum (FCS) and antibiotics, was
added to the T-25 flask and allowed to incubate at 37°C, 5%
CO2. Cell cultures were checked daily for cytopathic effect
(CPE), and after approximately 75% CPE was observed,
remaining cells were scraped off and combined with the super-
natant. A low-speed centrifugation removed most debris, and
the resulting supernatant was stored at -80°C. Some cells were
retained to perform immunofluorescence (IFA) directed at
RVFV to check for positive cultures. Two hundred microliters
of passage 1 cell/supernatant was placed into 1 mL of TriPure
(Roche, Indianapolis, IN) for RNA purification. Saudi Arabia
sample 2003043 and Yemen sample 2001373 were prepared
by placing 200 µL of blood or serum, respectively, directly
into 1 mL of TriPure. RNA was extracted onto glass beads by
using a RNAid kit (Bio101, Carlsbad, CA) according to a
modified protocol (7).
Indirect Immunofluorescence Assay and RT-PCR
Virus-infected cells were tested for RVFV antigens by
indirect immunofluorescence assay essentially as described
(5), except cells were incubated with anti-RVFV immune
mouse ascitic fluid.
The nucleic acid sequences of the partial S, M, and L seg-
ments of RVFVs were amplified by using a one-step reverse
transcriptase polymerase chain reaction (RT-PCR) (Promega
Access kit, Madison, WI), according to manufacturer’s proto-
col. The primers NSn (5′ - TATCATGGATTACTTTCC-3′ ) and
NSc (5′ - CCTTAACCTCTAATCAAC-3′ ) were used to
amplify a 661-Nt region (excluding primer sequences) of the
virus S segment region encoding the NSs protein (8). The
primers RVFFORI (5′ -GTCTTGCTTGAAAAGGGAAAA-3′ )
and RVFREVE (5′ -CCTGACCCATTAGCATG-3′ ) were used
to amplify a 708-Nt region (excluding primers) of the virus M
segment region encoding the G2 protein. Primers Wag (5'-
ATTCTTATTCCCGAATAT-3′ ) and Xg (5′ -TTGTTTTGC-
CTATCCTAC-3′ ) were used to amplify a 176-Nt (excluding
primers) region of the L segment (9). The primers RVFREVE
together with primer RVFFORA (5′ -TGCTACCAGACT-
CATTTGTC-3′ ) were used to amplify the initial diagnostic
fragment of 186 Nt (excluding primers) of the virus M RNA
genome segment region encoding the G2 protein.
Electrophoresis of amplified DNA products was done on a
1.7% agarose gel in Tris-acetate-EDTA buffer. Following stain-
ing with ethidium bromide, specific DNA bands were located
by UV translumination, sliced from the gel, and purified by
using Qiaquick spin columns (Qiagen, Valencia, CA). Dye ter-
minator cycle sequencing reactions were performed by using
ABI PRISM Dye Terminator Cycle Sequencing Ready Reac-
tion Kits with AmpliTaq DNA Polymerase FS (Applied Bio-
systems, Foster City, CA). Reaction products were purified by
using Centri-sep spin columns (Princeton Separations, Adel-
phia, NJ) and sequences determined with an ABI 377 auto-
mated DNA sequencer (Applied Biosystems). Output
chromatograms were analyzed with Sequencher 3.0 software
(Gene Codes Corp., Ann Arbor, MI). RVFV sequences were
aligned with those of previously characterized RVFVs (10) by
using the PILEUP program of the Wisconsin Package Version
10.2 (Genetics Computer Group, Inc., Madison, WI). Maxi-
mum likelihood phylogenetic analysis was carried out by using
PAUP4.0b10 (Sinauer Associates Inc., Sunderland, MA).
Results
Initial RVF Diagnosis
In early September 2000, the Ministry of Health of Saudi
Arabia received reports of unexplained hemorrhagic fever
cases in the southern Tehama (coastal plain) region of south-
western Saudi Arabia. Subsequently, reports were also
obtained by the Yemen Ministry of Health of a similar disease
in the adjoining Tehama region of Western Yemen. Initial
specimens included acute-phase sera from four hospitalized
patients with suspected cases and sera from nine contacts
(mostly family members). Based on the available clinical
information, the differential diagnostic included Rift Valley
fever, Crimean-Congo hemorrhagic fever, and Tick-borne
encephalitis-like viruses. The four serum samples from the
suspected case-patients were tested by antigen-capture ELISA
with RVFV- or C-CHFV-reactive antibodies; IgM-capture
ELISA with RVFV, C-CHFV, or Alkhurma virus–infected cell
lysate antigens; IgG ELISA with RVFV, C-CHVF, or
Alkhurma virus–infected cell slurry antigen; virus isolation
with Vero E6 cells; and RT-PCR assays for detection of RVFV,
C-CHFV, or TBE-complex virus RNA. Evidence of RVFV
infection was found in all four patients with suspected cases
(Table 1). No evidence of C-CHFV or Alkhurma virus infec-
tion was found. Three of four acute-phase sera were positive
by RVFV antigen-capture ELISA, and the single negative
serum was positive for RVFV IgM and IgG, suggesting a laterRESEARCH
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stage of infection in this case. All four sera were positive by
RVFV RT-PCR assay and subsequently yielded infectious
RVFV by culture on Vero E6 cells. 
Of the nine sera from close contacts, two showed evidence
of RVFV infection. One was RT-PCR positive and virus isola-
tion positive, and the other was positive for RVFV IgM anti-
bodies. A second shipment of specimens yielded similar
results, again confirming that RVFV was responsible for the
outbreak in Saudi Arabia. In this second shipment, 13 of 15
hospitalized suspected case-patients had evidence of RVFV
infection. Four contacts of case-patients also showed evidence
of RVFV infection.
The rapid RVFV RT-PCR assay appeared to be a useful
complement to the RVFV antigen and IgM-capture ELISA
tests for diagnosis of acute illness, as it detected virus RNA in
15 of 16 serum samples that were subsequently found to be
RVFV positive. Overall correlation between the various RVFV
diagnostic assays was good. Nucleotide sequence analysis of
the 186-Nt (excluding primer regions) PCR products amplified
from these initial specimens confirmed the virus identity as
RVFV and showed no nucleotide differences between the
viruses detected in these Saudi Arabian patients. In addition,
no nucleotide differences were detected in this 186-Nt region
relative to viruses detected in an earlier outbreak in East Africa
in 1997 (data not shown) (11).
Detailed Genetic Analysis
RNA extracted from three representative viruses was cho-
sen for more detailed genetic analysis. These included RNA
from RVFV isolate (strain 200010901) obtained from the first
RVFV-infected case-patient to be laboratory confirmed and
representing the early phase of the outbreak in Saudi Arabia.
This isolate was obtained from a serum sample collected on
September 13, 2000, from this case-patient (Table 1), who was
infected in Jizan Province. RNA extracted from a serum sam-
ple collected late in the outbreak in Saudi Arabia was also
included (Table 2). This serum sample was collected on
November 22, 2000, from a case-patient infected in Asir Prov-
ince. The third RNA sample was extracted from a blood sam-
ple obtained from a case-patient in Yemen. With these RNA
samples, we hoped to detect any genetic variation in the
RVFVs active during the early and late phases of the outbreak
in Saudi Arabia and to evaluate whether the same virus strain
was responsible for disease in Saudi Arabia and Yemen. 
A single nucleotide difference was observed between each
of the Saudi Arabia and Yemen virus S RNA genome segment
fragments analyzed (601 nt). Similarly, no nucleotide differ-
ences were found between the Saudi Arabia 200010901 and
Yemen 2003043 virus M RNA genome segment fragments we
analyzed (510 nt), and these differed from the Saudi Arabia
2001373 virus fragment by only 1 nt. All three viruses were
identical for the L RNA genome segment fragment we ana-
lyzed (129 nt). These data demonstrate that the viruses in the
early and late stages of the RVF outbreak in Saudi Arabia are
virtually identical to one another and to the virus causing dis-
ease in Yemen.
The results of phylogenetic analysis of the nucleotide
sequence differences among the S, M, and L RNA genome
fragments of the Saudi Arabia and Yemen viruses and previ-
ously described RVFVs are shown (Figure). Earlier maximum
likelihood analyses had separated RVFVs into three broad
groups, which predominantly contained viruses from North
Africa, West Africa, and East/Central Africa (10). All three
RNA segment trees obtained here have the Saudi Arabia and
Yemen viruses grouped with the East/Central Africa viruses.
Specifically, the S, M, and L RNA genome segments of the
Saudi Arabia and Yemen viruses are closely related to those of
viruses previously detected in outbreaks in East Africa, as rep-
resented by the Kenya 1997 and Madagascar 1991 virus iso-
lates (Figure, A, B, and C). The nucleotide changes in the S,
M, and L RNA genome segment fragments observed among
the closely related Saudi Arabia/Yemen viruses and the Kenya
1997 and Madagascar 1991 viruses are synonymous changes,
resulting in no amino acid differences among these viruses.
Discussion
Using a combination of RVFV IgM and antigen-capture
ELISA tests, along with the RT-PCR assay, we quickly identi-
fied RVFV as the cause of a large outbreak in Saudi Arabia
reported in September 2000. The RT-PCR assay proved to be
an excellent complement to the antigen and antibody ELISA
detection systems for the initial rapid diagnosis of RVF. Virus-
specific antibodies were present in three of four specimens that
were positive by both virus isolation and PCR but negative by
antigen capture, suggesting that immune complex formation
(antibody blocking of antigen) may be the basis for the lower
sensitivity of the antigen-capture assay. Although the IgM
assay failed to identify 9 of 17 laboratory-confirmed (by virus
isolation or PCR) acute RVF cases, the assay did detect recent
RVFV infections in five contacts (mostly close family mem-
bers) and one acute case that would have been missed on the
basis of virus isolation or PCR assay only. The data from this
study and others (12) demonstrate the importance of combin-
ing assays for the detection of virus (antigen capture, RT-PCR,
Table 2. Specimens chosen for more detailed virus genetic analysis, Saudi Arabia and Yemen
No. Collection date Location Specimen type Passage historya
200010901 Sept. 13, 2000 Jizan Province, Saudi Arabia Virus isolate P1
2001373 Nov. 22, 2000 Asir Province, Saudi Arabia Serum (human) NA
2003043 Oct. 28, 2000 Northwest Yemen Blood (human) NA
aP1, first passage; NA, not applicable.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1419
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or virus isolation) and the detection of virus-specific IgM to
ensure that no acutely ill RVFV patients are missed. 
This RVF outbreak, the first confirmed outside Africa,
illustrates the potential for this disease to spread to other
regions of the world. Virus activity on the Arabian Peninsula
resulted in a considerable amount of disease activity from Sep-
tember 2000 to February 2001 (3,13). In Saudi Arabia, as of
February 2001, 884 seriously ill, hospitalized RVF patients
were identified, with 124 deaths. In Yemen, 1,087 cases were
estimated to have occurred, with 121 deaths (14). The out-
break involved a broad geographic area, including Jizan and
Asir Provinces in southwestern Saudi Arabia and much of the
western coastal plain of Yemen. Because of the magnitude of
this outbreak and the large geographic area it encompassed,
the total number of human RVFV infections remains
unknown. Data from previous outbreaks suggest that the num-
ber of hospitalized RVF patients identified during a large out-
break represents only a small percentage (<1%) of the total
number of infections (2). Our finding of six laboratory-con-
firmed RVFV infections among household contacts is consis-
tent with the view that hospitalized patients represent a small
fraction of the number of infected persons. Based on these and
earlier observations, the number of human infections during
this epidemic must have been considerable. Large numbers of
livestock were also affected, causing substantial losses and
economic impact in the rural areas hardest hit by the disease.
Further impact of the outbreak included trade and travel
restrictions.
Genetic analysis of S, M, and L segments of the viruses
detected in Saudi Arabia and Yemen indicated that essentially
the same virus caused both outbreaks. Few genetic differences
were detected between viruses sampled early and late in the
outbreak or from the distant geographic regions of Jizan and
Asir Provinces in Saudi Arabia and areas of Western Yemen.
The lack of substantial genetic variation in these viruses,
together with the lack of earlier disease reports, suggests that
RVFV has only recently been introduced onto the Arabian
Peninsula.
Phylogenetic comparison of the nucleotide sequence dif-
ferences between the Arabian Peninsula RVFV S, M, and L
segments and those of previously characterized RVFV isolates
showed a close relationship between the Saudi Arabia/Yemen
RVFVs and those circulating earlier in East Africa, particu-
larly with the viruses responsible for the large RVF outbreak
seen in the region in 1997–98 (11). These results are consistent
with the introduction of RVFV into Saudi Arabia and Yemen
from East Africa. While genetic reassortment has been
observed in RVFVs associated with outbreaks in various geo-
graphic regions of Africa (10), the close phylogenetic relation-
ship of the S, M, and L RNA segments of the 2000–01 Saudi
Arabia and Yemen viruses and the earlier 1997 and 1991
Kenya and Madagascar viruses, respectively, provided no evi-
dence of genetic reassortment among these viruses.
The mechanism of introduction of the virus into the Saudi
Arabia and Yemen remains unknown. However, commercial
trade of livestock is active from East Africa to the Arabian
Peninsula, and disease is known to be endemic in the East
African region. While no hospitalized RVF patients have been
reported in 2002, whether this RVF lineage has become estab-
lished in the Arabian Peninsula remains unclear. Surveillance
of humans, livestock, and vector populations will continue to
address this question.
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